Literature DB >> 21887484

Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.

Hui-Lin Yang1, Tao Liu, Xi-Ming Wang, Yong Xu, Sheng-Ming Deng.   

Abstract

OBJECTIVE: To perform a meta-analysis to compare (18)FDG PET, CT, MRI and bone scintigraphy (BS) for the diagnosis of bone metastases.
METHODS: Databases including MEDLINE and EMBASE were searched for relevant original articles published from January 1995 to January 2010. Software was used to obtain pooled estimates of sensitivity, specificity and summary receiver operating characteristic curves (SROC).
RESULTS: 67 articles consisting of 145 studies fulfilled all inclusion criteria. On per-patient basis, the pooled sensitivity estimates for PET, CT, MRI and BS were 89.7%, 72.9%, 90.6% and 86.0% respectively. PET=MRI>BS>CT. ("="indicated no significant difference, P > 0.05; ">" indicated significantly higher, P < 0.05). The pooled specificity estimates for PET, CT, MRI and BS were 96.8%, 94.8%, 95.4% and 81.4% respectively. PET = CT = MRI>BS. On per-lesion basis, the pooled sensitivity estimates for PET, CT, MRI and BS were 86.9%, 77.1%, 90.4% and 75.1% respectively. PET = MRI>BS>CT. The pooled specificity estimates for PET, CT, MRI and BS were 97.0%, 83.2%, 96.0% and 93.6% respectively. PET>MRI>BS>CT.
CONCLUSION: PET and MRI were found to be comparable and both significantly more accurate than CT and BS for the diagnosis of bone metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887484     DOI: 10.1007/s00330-011-2221-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  91 in total

Review 1.  Bone marrow imaging.

Authors:  J B Vogler; W A Murphy
Journal:  Radiology       Date:  1988-09       Impact factor: 11.105

Review 2.  Radiological imaging for the diagnosis of bone metastases.

Authors:  L D Rybak; D I Rosenthal
Journal:  Q J Nucl Med       Date:  2001-03

Review 3.  The role of positron emission tomography in the management of bone metastases.

Authors:  G J Cook; I Fogelman
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

4.  Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.

Authors:  R Lebtahi; G Cadiot; N Delahaye; R Genin; D Daou; M C Peker; D Chosidow; M Faraggi; M Mignon; D Le Guludec
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

5.  Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.

Authors:  R Venkitaraman; G J R Cook; D P Dearnaley; C C Parker; V Khoo; R Eeles; R A Huddart; A Horwich; S A Sohaib
Journal:  J Med Imaging Radiat Oncol       Date:  2009-06       Impact factor: 1.735

6.  Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Authors:  Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

7.  99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.

Authors:  Bieke Van Den Bossche; Eveline D'haeninck; Frederic De Winter; Simon Van Belle; Rudi A Dierckx; Christophe Van De Wiele
Journal:  Nucl Med Commun       Date:  2004-08       Impact factor: 1.690

8.  Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.

Authors:  S A Sohaib; G Cook; S D Allen; M Hughes; T Eisen; M Gore
Journal:  Br J Radiol       Date:  2009-02-16       Impact factor: 3.039

9.  Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET?

Authors:  Ha T T Phan; Pieter L Jager; John T M Plukker; Bruce H R Wolffenbuttel; Rudi A Dierckx; Thera P Links
Journal:  Nucl Med Commun       Date:  2007-08       Impact factor: 1.690

10.  The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.

Authors:  Joo-Won Min; Sang-Won Um; Jae-Jun Yim; Chul-Gyu Yoo; Sung Koo Han; Young-Soo Shim; Young Whan Kim
Journal:  J Korean Med Sci       Date:  2009-04-21       Impact factor: 2.153

View more
  70 in total

Review 1.  Imaging of bone metastasis: An update.

Authors:  Gerard J O'Sullivan; Fiona L Carty; Carmel G Cronin
Journal:  World J Radiol       Date:  2015-08-28

2.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

3.  Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Authors:  Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan
Journal:  Acad Radiol       Date:  2018-04-04       Impact factor: 3.173

4.  Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Authors:  Caroline Rousseau; David M Goldenberg; Mathilde Colombié; Jean-Charles Sébille; Philippe Meingan; Ludovic Ferrer; Pierre Baumgartner; Evelyne Cerato; Damien Masson; Mario Campone; Aurore Rauscher; Vincent Fleury; Catherine Labbe; Alain Faivre Chauvet; Jean-Sebastien Fresnel; Claire Toquet; Jacques Barbet; Robert M Sharkey; Loic Campion; Françoise Kraeber-Bodéré
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

5.  Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.

Authors:  Stuart A Taylor; Susan Mallett; Anne Miles; Stephen Morris; Laura Quinn; Caroline S Clarke; Sandy Beare; John Bridgewater; Vicky Goh; Sam Janes; Dow-Mu Koh; Alison Morton; Neal Navani; Alfred Oliver; Anwar Padhani; Shonit Punwani; Andrea Rockall; Steve Halligan
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

Review 6.  MRI for response assessment in metastatic bone disease.

Authors:  F E Lecouvet; A Larbi; V Pasoglou; P Omoumi; B Tombal; N Michoux; J Malghem; R Lhommel; B C Vande Berg
Journal:  Eur Radiol       Date:  2013-03-01       Impact factor: 5.315

Review 7.  [Imaging diagnostics in bone metastases].

Authors:  L Kintzelé; M-A Weber
Journal:  Radiologe       Date:  2017-02       Impact factor: 0.635

8.  Bone metastases of the hand.

Authors:  G Morris; S Evans; J Stevenson; A Kotecha; M Parry; L Jeys; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2017-09       Impact factor: 1.891

9.  Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.

Authors:  Albert Chau; Peter Gardiner; Patrick M Colletti; Hossein Jadvar
Journal:  Clin Nucl Med       Date:  2018-07       Impact factor: 7.794

10.  Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.

Authors:  Christian Uprimny; Anna Svirydenka; Josef Fritz; Alexander Stephan Kroiss; Bernhard Nilica; Clemens Decristoforo; Roland Haubner; Elisabeth von Guggenberg; Sabine Buxbaum; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.